Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead
Philip Morris International shares rose 0.8% to $172.48 Thursday after the company reported over $20 billion in U.S.-related investments since 2022. Attention is turning to an FDA panel review of ZYN nicotine pouch “modified risk” claims on Jan. 22, with a company results webcast set for Feb. 6.